Stay updated on Galegenimab in Geographic Atrophy AMD: Clinical Trial
Sign up to get notified when there's something new on the Galegenimab in Geographic Atrophy AMD: Clinical Trial page.

Latest updates to the Galegenimab in Geographic Atrophy AMD: Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedAdded an extensive Locations section listing study sites by state and updated to Revision: v3.3.3. Removed the prior state-specific location blocks (Arizona Locations, California Locations, etc.).SummaryDifference2%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2. This appears to be a backend version update with no visible changes to study content or page layout.SummaryDifference0.0%

- Check39 days agoChange DetectedThe page shows Revision: v3.3.1, replacing the previous Revision: v3.2.0.SummaryDifference0.0%

- Check46 days agoChange DetectedDeleted the funding/operating status notice related to government funding. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check61 days agoChange DetectedResults have been posted for the GALLEGO study (Results First Posted 2024-03-27). The study status is Terminated due to an unfavorable benefit–risk balance.SummaryDifference0.3%

- Check89 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference3%

Stay in the know with updates to Galegenimab in Geographic Atrophy AMD: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Galegenimab in Geographic Atrophy AMD: Clinical Trial page.